Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease

Polymyositis (PM) and dermatomyositis (DM) are subtypes of autoimmune inflammatory myopathies. Interstitial lung disease (ILD) involvement is common in PM/DM. There is no evidence base for immunosuppression in DM/PM-ILD and current evidence is based on case stories and expert opinions. We present a...

Descripción completa

Detalles Bibliográficos
Autores principales: Peshbahar, Soran, Bendstrup, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594835/
https://www.ncbi.nlm.nih.gov/pubmed/33224454
http://dx.doi.org/10.1080/20018525.2020.1840706
_version_ 1783601707762057216
author Peshbahar, Soran
Bendstrup, Elisabeth
author_facet Peshbahar, Soran
Bendstrup, Elisabeth
author_sort Peshbahar, Soran
collection PubMed
description Polymyositis (PM) and dermatomyositis (DM) are subtypes of autoimmune inflammatory myopathies. Interstitial lung disease (ILD) involvement is common in PM/DM. There is no evidence base for immunosuppression in DM/PM-ILD and current evidence is based on case stories and expert opinions. We present a 63-year-old male with severe respiratory failure due to PM-ILD who was treated successfully with intravenous immunoglobulin, recovered the acute phase and survived more than 4 years.
format Online
Article
Text
id pubmed-7594835
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-75948352020-11-19 Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease Peshbahar, Soran Bendstrup, Elisabeth Eur Clin Respir J Case Report Polymyositis (PM) and dermatomyositis (DM) are subtypes of autoimmune inflammatory myopathies. Interstitial lung disease (ILD) involvement is common in PM/DM. There is no evidence base for immunosuppression in DM/PM-ILD and current evidence is based on case stories and expert opinions. We present a 63-year-old male with severe respiratory failure due to PM-ILD who was treated successfully with intravenous immunoglobulin, recovered the acute phase and survived more than 4 years. Taylor & Francis 2020-10-26 /pmc/articles/PMC7594835/ /pubmed/33224454 http://dx.doi.org/10.1080/20018525.2020.1840706 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Peshbahar, Soran
Bendstrup, Elisabeth
Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease
title Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease
title_full Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease
title_fullStr Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease
title_full_unstemmed Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease
title_short Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease
title_sort remarkable benefits of intravenous immunoglobulin (ivig) in a patient with polymyositis-associated acute interstitial lung disease
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594835/
https://www.ncbi.nlm.nih.gov/pubmed/33224454
http://dx.doi.org/10.1080/20018525.2020.1840706
work_keys_str_mv AT peshbaharsoran remarkablebenefitsofintravenousimmunoglobuliniviginapatientwithpolymyositisassociatedacuteinterstitiallungdisease
AT bendstrupelisabeth remarkablebenefitsofintravenousimmunoglobuliniviginapatientwithpolymyositisassociatedacuteinterstitiallungdisease

Ejemplares similares